Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs

• Egile nagusia: Umberto Malapelle (auth)
• Beste egile batzuk: Pierlorenzo Pallante (auth)
• Formatua: Baliabide elektronikoa Liburu kapitulua
• Hizkuntza: ingelesa
• Argitaratua: Frontiers Media SA 2017
• Saila: Frontiers Research Topics
• Gaiak: Medicine; Alectinib; Liquid Biopsy; Non-Small Cell Lung Cancer; Afatinib; Nivolumab; Immunotherapy; Nintedanib; Dacomitinib; Second-Line Treatment; Tyrosine Kinase Inhibitor
• Sarrera elektronikoa: DOAB: download the publication; DOAB: description of the publication

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therap...